Scilex Holding Co SCLX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if SCLX is a good fit for your portfolio.
News
-
Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (Nasdaq: DECA) Enter into a Letter of Intent for a Proposed Business Combination
-
Scilex Holding Company to Ring Nasdaq Closing Bell on Friday, July 5th at 4:00PM ET at the Nasdaq MarketSite in Times Square, New York
-
Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results for the Month Ended June 30, 2024 and Second Quarter of 2024
-
Scilex Holding Company Partners with New National Distributor, Endeavor Distribution LLC.
-
Scilex Holding Company Announces Publication in PAIN Journal Regarding Phase 3 Results of the Pivotal Registration Trial of SP-102 (SEMDEXA™) in Lumbosacral Radicular Pain (Sciatica)
-
Scilex Holding Company to Present Poster on ELYXYB® (celecoxib oral solution) at the 66th Annual Scientific Meeting of the American Headache Society (AHS) to be Held in San Diego, CA on June 13-16, 2024
-
Scilex Holding Company Announces 5-Year Term of $100 Million Financing with Royalty-Based Payments and Potential Strategic Transactions with Perigrove and its Portfolio Companies
-
Scilex Holding Company Announces That Many National Pharmacy Chains and Independent Pharmacies Have Begun Stocking GLOPERBA®
Trading Information
- Previous Close Price
- $1.84
- Day Range
- $1.72–1.89
- 52-Week Range
- $0.73–6.54
- Bid/Ask
- $1.89 / $1.90
- Market Cap
- $228.92 Mil
- Volume/Avg
- 952,598 / 1.3 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 4.61
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Small Growth
- Total Number of Employees
- 105
- Website
- https://www.scilexholding.com
Comparables
Valuation
Metric
|
SCLX
|
FINN
|
ESQ
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | 10.10 |
Price/Book Value | — | — | 1.88 |
Price/Sales | 4.61 | — | 3.47 |
Price/Cash Flow | — | — | 8.42 |
Price/Earnings
SCLX
FINN
ESQ
Financial Strength
Metric
|
SCLX
|
FINN
|
ESQ
|
---|---|---|---|
Quick Ratio | 0.12 | — | — |
Current Ratio | 0.15 | — | — |
Interest Coverage | −66.47 | — | — |
Quick Ratio
SCLX
FINN
ESQ
Profitability
Metric
|
SCLX
|
FINN
|
ESQ
|
---|---|---|---|
Return on Assets (Normalized) | −107.39% | 0.95% | 2.54% |
Return on Equity (Normalized) | — | 11.53% | 20.67% |
Return on Invested Capital (Normalized) | — | — | — |
Return on Assets
SCLX
FINN
ESQ
Drug Manufacturers - General Industry Comparables
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|---|
Eli Lilly and Co
LLY
| Lyyrvvklq | Nrvq | $808.7 Bil | |||
Johnson & Johnson
JNJ
| Pgdspmx | Mbry | $350.6 Bil | |||
Merck & Co Inc
MRK
| Kvyjfxly | Mztkp | $318.8 Bil | |||
AbbVie Inc
ABBV
| Vctydzy | Fbjgn | $289.3 Bil | |||
AstraZeneca PLC ADR
AZN
| Yhtynlpykl | Ltbk | $239.2 Bil | |||
Novartis AG ADR
NVS
| Txfsrnkyb | Dzmw | $220.2 Bil | |||
Roche Holding AG ADR
RHHBY
| Ddhwbhjmz | Bsxqp | $218.3 Bil | |||
Amgen Inc
AMGN
| Yxrfqmdkx | Grc | $166.0 Bil | |||
Pfizer Inc
PFE
| Vkzlcrq | Vkwf | $157.0 Bil | |||
Sanofi SA ADR
SNY
| Xxnnrgk | Zzsp | $122.8 Bil |